• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Trials Should Include Patients Who Haven’t Received Prior Treatment

Cancer Trials Should Include Patients Who Haven’t Received Prior Treatment

June 28, 2021

The FDA has published draft guidance for trial investigators and sponsors, recommending that patients with incurable cancers be considered for oncology trials regardless of whether they have received existing alternative treatment options.

Many trials have historically required that participants previously received multiple therapies. But according to the guidance, the FDA believes that incurable cancer patients, if given sufficient information to make an informed decision, should be eligible for participation in cancer trials even if they haven’t tried existing alternative treatment options for their cancer.

“If there is no scientific rationale for excluding these patients, then clinical trial eligibility criteria should be broadened to include these patients, with appropriate informed consent,” the guidance says. “With appropriate informed consent, patients may be eligible for inclusion in trials of investigational drugs, including first-in-human trials, regardless of whether they have received available therapy in the noncurative setting.”

In addition to disclosing appropriate alternative procedures or courses of treatment, if any, that could help the patient, the informed consent should clearly state that other treatment options known to provide benefit exist and should include a discussion of the possible benefits, risks and uncertainties associated with the investigational drug.

The agency also advised sponsors and investigators to consider evaluating patients who have been given available therapies and patients who haven’t in separate cohorts, particularly if a homogenous patient population is needed to evaluate efficacy.

Trials evaluating investigational cancer drugs should require that patients, in general, have received available therapies that offer a potential cure in a substantial proportion of patients, the guidance says.

“However, eligibility criteria in which patients receive an investigational drug(s) in lieu of available therapy is reasonable in the noncurative setting (i.e., there is no potential for cure or for prolonged/near normal survival) when patients have been provided adequate information to make an informed decision on trial participation,” the guidance states.

Comments are due on the draft guideline by Aug. 24.

Read the full guidance here: https://bit.ly/3A5y6ZQ.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing